Appendix 4c – q2 fy25 quarterly cash flow report

Highlights topline data for ath434-201 randomized, double-blind phase 2 clinical trial on track for expected release by early february 2025 ath434-201 trial in early-stage msa completed in november 2024 positive interim data presented at mds from the ath434-202 phase 2 trial in advanced msa multiple data presentations and publications showing the potential for ath434 to modify disease progression in neurodegenerative conditions cash balance on 31 december 2024 of a$4.54 m melbourne, australia and san francisco, jan. 24, 2025 (globe newswire) -- alterity therapeutics (asx: ath, nasdaq: athe) (“alterity” or “the company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its appendix 4c quarterly cash flow report and update on company activities for the quarter ending 31 december 2024 (q2 fy25). “the second fiscal quarter of this year was extremely productive for alterity and highlighted the tremendous potential of our lead asset, ath434, as a promising therapy to treat a variety of neurodegenerative diseases,” said, david stamler, m.d.
MSA Ratings Summary
MSA Quant Ranking